References
- Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol. 2004;61:1613–1615.
- Boissy AR, Cohen JA. Multiple sclerosis symptom management. Expert Rev Neurother. 2007;7:1213–1222.
- Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9:520–532.
- Grattan DR, Kokay IC. Prolactin: a pleiotropic neuroendocrine hormone. J Neuroendocrinol. 2008;20:752–763.
- Ben-Jonathan N, Mershon JL, Allen DL, et al. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17:639–669.
- Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523–1631.
- Yong VW. Prospects of repair in multiple sclerosis. J Neurol Sci. 2009;277(Suppl 1):S16–S18.
- Chikanza IC. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann NY Acad Sci. 1999;876:119–130.
- Grinsted L, Heltberg A, Hagen C, et al. Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis. J Intern Med. 1989;226:241–244.
- Kira J, Harada M, Yamaguchi Y, et al. Hyperprolactinemia in multiple sclerosis. J Neurol Sci. 1991;102:61–66.
- Yamasaki K, Horiuchi I, Minohara M, et al. Hyperprolactinemia in optico-spinal multiple sclerosis. Intern Med. 2000;39:296–299.
- Harirchian MH, Sahraian MA, Shirani A. Serum prolactin level in patients with multiple sclerosis: a case control study. Med Sci Monit. 2006;12:CR177–CR180.
- Heesen C, Gold SM, Bruhn M, et al. Prolactin stimulation in multiple sclerosis–an indicator of disease subtypes and activity? Endocr Res. 2002;28:9–18.
- Nakken B, Szodoray P. Accelerated atherosclerosis in rheumatoid arthritis: rationale for mannose-binding lectins? J Rheumatol. 2010;37:482–484.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
- Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
- Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
- Moshirzadeh S, Ghareghozli K, Harandi AA, et al. Serum prolactin level in patients with relapsing-remitting multiple sclerosis during relapse. J Clin Neurosci Title. 2012;19:622–623.
- Markianos M, Koutsis G, Evangelopoulos ME, et al. Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis. J Neuroendocrinol. 2010;22:503–508.
- Nabavi SM, Koupai SA, Nejati MR, et al. Menstrual irregularities and related plasma hormone levels in multiple sclerosis patients treated with beta interferone. Acta Med Iran. 2008;48:36–41.
- Heesen C, Schulz H, Schmidt M, et al. Endocrine and cytokine responses to acute psychological stress in multiple sclerosis. Brain Behav Immun. 2002;16:282–287.
- Azar ST, Yamout B. Prolactin secretion is increased in patients with multiple sclerosis. Endocr Res. 1999;25:207–214.
- Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846.
- Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev. 1996;17:64–102.
- Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev. 2007;6:537–542.
- Riskind PN, Massacesi L, Doolittle TH, et al. The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol. 1991;29:542–547.
- Wei T, Lightman SL. The neuroendocrine axis in patients with multiple sclerosis. Brain. 1997;120(Pt 6):1067–1076.